Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

SHE:301258 Revenue

Suzhou Fushilai Pharmaceutical had revenue of 79.57M CNY in the quarter ending September 30, 2026, a decrease of -19.36%. This brings the company's total for the last twelve months to 375.19M, down -14.65% year-over-year. In the year 2025, Suzhou Fushilai Pharmaceutical had annual revenue of 432.73M with 0.76% growth. That makes Suzhou Fushilai Pharmaceutical the 27,110th largest company in the world by revenue and 4,726th in China.

• Revenue (ttm): 375.19M
• Revenue Growth: -14.65%
• P/S Ratio: 5.62
• Revenue / Employee: 694.80K
• Employees: 540
• Market Cap: 2.11B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Business 427.18M 98.7%
• Unallocated Other Business 5.55M 1.3%

By Geography

Chart

• China 234.30M 54.1%
• Abroad 198.43M 45.9%

Fiscal year ended Dec 31, 2025 See the full SHE:301258 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	432.73M	3.26M	0.76%
Dec 31, 2024	429.47M	-59.82M	-12.23%
Dec 31, 2023	489.29M	-78.92M	-13.89%
Jan 1, 2023	568.21M	46.52M	8.92%
Jan 1, 2022	521.70M	44.85M	9.40%

Data Source: S&P Global Market Intelligence Last updated: Oct 22, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error